Drug
Revefenacin Inhalation Yupelri
Revefenacin Inhalation Yupelri: highest development phase Phase 2, developed by Theravance Biopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Revefenacin Inhalation Solution [Yupelri] NCT04315558 | Phase 2 | COPD |
Latest
No recent events.
Follow Revefenacin Inhalation Yupelri on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.